UK Must Use Biosimilar Savings To Provide Earlier Access To Biologics
Executive Summary
The UK may be busy sweeping up the savings being generated with the rapid uptake of biosimilars, but more needs to be done to show how this money is being channelled back into the healthcare system to the benefit of patients.